Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 16, Number 9—September 2010

Research

Pediatric Pneumococcal Serotypes in 4 European Countries

Germaine Hanquet1Comments to Author , Esther Kissling, Asuncion Fenoll, Robert C. George, Agnes Lepoutre, Tinne Lernout, David Tarragó, Emmanuelle Varon, and Jan Verhaegen
Author affiliations: Author affiliations: Scientific Institute of Public Health, Brussels, Belgium (G. Hanquet, E. Kissling, T. Lernout); Belgian Knowledge Centre, Brussels (G. Hanquet); Instituto de Salud Carlos III, Madrid, Spain (A. Fenoll, D. Tarragó,); Health Protection Agency, London, UK (R. George); Institut de Veille Sanitaire, Saint Maurice, France (A. Lepoutre); Hôpital Européen G. Pompidou, Paris, France (E. Varon); Katholieke Universiteit Leuven Pneumococcus Reference Laboratory, Leuven, Belgium (J. Verhaegen)

Main Article

Table 3

Serotype-specific adjusted incidence rates of invasive pneumococcal disease in children 5–14 years of age before and after marketing of PCV7, Spain, Belgium, France, and England and Wales*

Country/serotype      Incidence rate†
Relative risk
(95% CI) p value
Prevaccine (1999–2002) Postmarketing (2005–2006)
Spain
PCV7 types 1.0 0.8 0.8 (0.6–1.3) 0.387
Non-PCV7 types 2.1 4.6 2.2 (1.8–2.7) <0.001
1 1.1 3.1 2.9 (2.3–3.7) <0.001
7F 0.1 0.2 2.0 (0.7–5.6) 0.175
19A
0.06
0.12
2.1 (0.5–7.7)
0.226
Belgium
PCV7 types 3.0 1.2 0.4 (0.2–0.7) <0.001
Non-PCV7 types 3.9 6.1 1.6 (1.2–2.1) 0.003
1 2.2 3.8 1.8 (1.2–2.6) 0.003
7F 0.2 0.3 1.2 (0.2–5.2) 0.728
19A
0.3
0.1
0.2 (0.0–1.4)
0.094
France
PCV7 types 0.7 0.8 1.1 (0.7–1.6) 0.664
Non-PCV7 types 1.3 2.0 1.5 (1.2–2.0) 0.001
1 0.6 1.3 2.3 (1.6–3.4) <0.001
7F 0.0 0.1 3.6 (1.0–20.2) 0.038
19A
0.1
0.0
0.3 (0.0–1.6)
0.116
England and Wales
PCV7 types 0.7 1.0 1.4 (1.0–1.9) 0.026
Non-PCV7 types 0.7 2.0 2.9 (2.3–3.6) <0.001
1 0.3 1.3 4.2 (3.0–5.9) <0.001
7F 0.0 0.2 5.5 (1.9–18.0) 0.001
19A 0.05 0.1 2.1 (0.7–5.9) 0.148

*PCV7, heptavalent pneumococcal conjugate vaccine; CI, confidence interval. Marketing indicates that the vaccine was marketed and available for use in the country but not introduced in the vaccine schedule free of charge. Vaccine coverage differed by country during this period, ranging from 33% to 48% in Spain, Belgium, and France but <1% in England and Wales. PCV7 types include serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F.
†Cases per 100,000 children 5–14 years of age. Data for 1999–2002 are annual averages. Prevaccine period is 2001–2002 for France (data not available for previous years).

Main Article

1Current affiliation: Belgian Healthcare Agency, Brussels, Belgium.

TOP